Failure of NMDA receptor hypofunction to induce a pathological reduction in PV-positive GABAergic cell markers
Research highlights
▶ Parvalbumin expression is unaffected by a serine racemase null mutation. ▶ Parvalbumin expression is unaffected by subchronic dosing of PCP and ketamine. ▶ NMDAR hypofunction may not be a cause for PV-positive interneuron pathologies.
Section snippets
Acknowledgements
This research was supported by NIH Grants MH05129 (JTC) and P50 MH060450 (JTC). We thank Jiamin Feng for genotyping and maintaining our animal colony. We thank Dr. Sabina Berretta and Dr. Harry Pantazopoulos for their assistance with the immunohistochemical studies.
References (39)
- et al.
Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics
Schizophr. Res.
(1997) - et al.
GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder
Neuropsychopharmacology
(2001) - et al.
Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism
Schizophr. Res.
(2007) The GABA-glutamate connection in schizophrenia: which is the proximate cause?
Biochem. Pharmacol.
(2004)- et al.
Disturbances in social interaction occur along with pathophysiological deficits following sub-chronic phencyclidine administration in the rat
Behav. Brain Res.
(2008) - et al.
Effect of subchronic phencyclidine administration on sucrose preference and hippocampal parvalbumin immunoreactivity in the rat
Neurosci. Lett.
(2010) - et al.
The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia
Neuropsychopharmacology
(1999) - et al.
Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia
Neuroscience
(2004) - et al.
Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia
Trends Neurosci.
(2008) - et al.
Effect of pretreatment with risperidone on phencyclidine-induced disruptions in object recognition memory and prefrontal cortex parvalbumin immunoreactivity in the rat
Behav. Brain Res.
(2010)
A pharmacological model for psychosis based on N-methyl-d-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities
Biol. Psychiatry
Alpha(7) nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment
Neuropharmacology
Opposite effect of phencyclidine on activity-regulated cytoskeleton-associated protein (Arc) in juvenile and adult limbic rat brain regions
Neurochem. Int.
Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat
J. Psychopharmacol.
Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics
Arch. Gen. Psychiatry
Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior
Mol. Psychiatry
Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase
Science
Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia
J. Neurosci.
Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes
Nat. Neurosci.
Cited by (26)
The positive allosteric modulator of the mGlu2 receptor JNJ-46356479 partially improves neuropathological deficits and schizophrenia-like behaviors in a postnatal ketamine mice model
2020, Journal of Psychiatric ResearchCitation Excerpt :This is consistent with results from human postmortem studies that have shown a selective reduction in PV exclusively within the PFC (Beasley and Reynolds, 1997) and HPC (Zhang and Reynolds, 2002) from patients with SZ, suggesting a dysfunction of GABAergic interneurons in these brain areas involved in several cognitive processes. Given the disparate methodologies used with different animal models, conflicting results on PV changes have also been reported (Benneyworth et al., 2011), and the age of animals seems to be a relevant factor to take into account (Honeycutt and Chrobak, 2018). Most studies have used NMDAR antagonists in adulthood.
Hippocampal GABA<inf>A</inf> antagonism reverses the novel object recognition deficit in sub-chronic phencyclidine-treated rats
2018, Behavioural Brain ResearchCitation Excerpt :How this relates to the ability of local administration of bicuculline into the vHPC to restore NOR in the scPCP-treated rats remains to be determined. Previous studies using diverse regimens of NMDAR antagonists have produced inconsistent effects on GABAergic markers in various brain regions [57–59]. Such inconsistencies may be explained, in part, by the developmental window during which the NMDA antagonists were administered as the maturation of the GABAergic system in the cortex and HPC continues postnatally [60,61].